#OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies population: > Improvement of axial symptoms on upadacitinib across several outcomes compared to PLC! > 1new onset of uveitis on upadacitinib #EULAR2021 @RheumNow https://t.co/9YK1OYEorq